# Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma

> **NCT00004066** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 82 (estimated)

## Conditions studied

- Ovarian Cancer
- Sarcoma
- Small Intestine Cancer

## Interventions

- **BIOLOGICAL:** filgrastim
- **DRUG:** docetaxel
- **DRUG:** gemcitabine hydrochloride

## Key facts

- **NCT ID:** NCT00004066
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-06
- **Primary completion:** 2003-10
- **Final completion:** 2003-10
- **Target enrollment:** 82 (ESTIMATED)
- **Last updated:** 2013-03-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004066, "Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00004066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*